• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2021, Vol. 38 ›› Issue (2): 111-114.

• 药品评价 • 上一篇    下一篇

奥马珠单抗治疗儿童及青少年过敏性哮喘的系统评价

王亚芹, 樊鹏利, 吕品, 陈博雅, 李坤, 马培志*   

  1. 河南省人民医院药学部, 河南 郑州 450003
  • 收稿日期:2021-01-11 修回日期:2021-01-20 出版日期:2021-04-28 发布日期:2021-04-28
  • 基金资助:
    国家自然科学基金 81803357 (新型PIM/AKT双重抑制剂的设计合成及抗前列腺癌活性研究);中国药学会科技开发中心科普项目(CMEI2020KPYJ00610)

Treatment of Omalizumabon Allergic Asthma in Children and Adolescents: A Systematic Review

WANG Ya-qin, FAN Peng-li, LV Pin, CHEN Bo-ya, LI Kun, MA Pei-zhi*   

  1. Department of Pharmacy, Henan Provincial People′s Hospital, Henan Zhengzhou 450003, China
  • Received:2021-01-11 Revised:2021-01-20 Online:2021-04-28 Published:2021-04-28

摘要: 目的:对奥马珠单抗用于儿童及青少年过敏性哮喘的临床研究进行系统评价和Meta分析。方法:通过检索Pubmed、Medline和中国知网等数据库文献,截止日期为2020年6月21日。由2人进行文献筛选、资料提取以及质量评价,利用RevMan 5.3进行Meta分析。结果: 共纳入4篇随机对照研究,包含1 678例受试者。奥马珠单抗组哮喘恶化的风险较安慰剂组显著降低 [RR=0.63, 95%CI:(0.56, 0.71), Z=7.37, P<0.000 01],奥马珠单抗组哮喘治疗效果评级为优秀和良好的比例高于安慰剂组。奥马珠单抗治疗组不良反应和严重不良反应发生率均较低。结论: 奥马珠单抗可显著降低儿童及青少年患者的哮喘重度恶化率,提高患者生活质量,且耐受性较好。
  

关键词: font-size:medium, ">奥马珠单抗;过敏性哮喘;IgE抗体;Meta分析;哮喘重度恶化

Abstract: Objective: To conduct a systematic review about the treatment of omalizumab on allergic asthma in children and adolescents. Methods: The databases including Pubmed, Medline and China National Knowledge Internet were searched by computer and deadline was June 21, 2020. Two investigators screened studies, extracted data and evaluated quality of literatures, and Meta-analyses was conducted by RevMan 5.3. Results: Four randomized controlled trials involved in 1 678 subjects were included. Compared with placebo, the rate of asthma exacerbation was significantly reduced in patients treated with omalizumab [RR=0.63, 95%CI:(0.56, 0.71), Z=7.37, P<0.000 01]. The proportion of patients, who′s therapeutic effects were excellent or good when treated with omalizumab, was higher than those with placebo. The numbers of adverse reactions and severe adverse reactions with omalizumab were low. Conclusion: Omalizumab reduced rate of asthma exacerbation in children and adolescents, improved patients′ quality of life and was well tolerated.

Key words: font-size:medium, ">Omalizumab; Allergic asthma; IgE antibody; Meta-analyses; Asthma exacerbation

中图分类号: